Robaxin and Glossitis - a phase IV clinical study of FDA data

Summary:

Glossitis is reported as a side effect among people who take Robaxin (methocarbamol), especially for people who are female, 50-59 old, also take Gabapentin, and have High blood cholesterol.

The phase IV clinical study analyzes which people have Glossitis when taking Robaxin. It is created by eHealthMe based on reports of 8,252 people who have side effects when taking Robaxin from the FDA, and is updated regularly.

What is Robaxin?

Robaxin has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 9,109 Robaxin users. Check the latest studies of Robaxin.

What is Glossitis?

Glossitis (infection of tongue with soreness) is found to be associated with 530 drugs and 867 conditions by eHealthMe. Check the latest studies of Glossitis.

On Jun, 11, 2026

8,252 people reported to have side effects when taking Robaxin.
Among them, 42 people (0.51%) have Glossitis.

Among these 42 people:

What is the gender of people who have Glossitis when taking Robaxin? *

female: 76.19 %
male: 23.81 %

What is the age of people who have Glossitis when taking Robaxin? *

What are other drugs people take besides Robaxin? *

What are other side effects people have besides Glossitis? *

Fall: 41 people, 97.62%
Dizziness: 37 people, 88.10%
Hiatal Hernia (hernia resulting from the protrusion of part of the stomach through the diaphragm): 37 people, 88.10%
Sleep Apnea Syndrome: 36 people, 85.71%
Pain In Extremity: 33 people, 78.57%
Emotional Distress: 31 people, 73.81%
Infection: 31 people, 73.81%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 31 people, 73.81%
Injury: 31 people, 73.81%
Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 31 people, 73.81%

What are the existing conditions these people have? *

High Blood Cholesterol: 10 people, 23.81%
Breast Cancer: 8 people, 19.05%
Reflux Oesophagitis (an oesophageal mucosal injury that occurs of gastric contents into the oesophagus): 5 people, 11.90%
Osteoporosis (bones weak and more likely to break): 4 people, 9.52%
Multiple Myeloma (cancer of the plasma cells): 4 people, 9.52%
Metastases To Bone (cancer spreads to bone): 4 people, 9.52%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 4.76%
Sleep Disorder: 1 person, 2.38%
Nervousness: 1 person, 2.38%
Nervous System Disorder (a general class of medical conditions affecting the nervous system): 1 person, 2.38%

* Approximation only. Some reports may have incomplete information.

Do you take Robaxin and have Glossitis?

- Check whether Glossitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Robaxin:

Robaxin (9,109 reports)

Glossitis treatments and more:

Glossitis (5,292 reports)

Browse all side effects of Robaxin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Glossitis:

Glossitis (530 drugs)

Browse all the conditions that are associated with Glossitis:

Glossitis (867 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on methocarbamol (the active ingredients of Robaxin) and Robaxin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.